Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.

Related Keywords

Australia ,Canada ,Japan ,India ,Australian ,Biosimilar Bevacizumab ,Matt Erick ,Biocon Biologics ,Biocon Ltd ,Biosimilars Newco ,Twitter ,Un Sustainable Development Goals Sdgs ,Biocon Biologics Company ,Biocon ,Biocon Biologics Ltd ,Biocon Biologic ,Chief Commercial Officer ,Advanced Markets ,Pharmaceutical Benefits Scheme ,Biosimilars Newco Limited ,Biocon Biologics Limited ,Development Goals ,Generic Formulations ,Sandoz Ag ,Pharmaceutical Company ,